Study of BM230 for advanced solid tumors with HER2
Part of Cancer clinical trials.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with an advanced solid tumor that has HER2 expression or mutation.
- You need to have had standard treatment that no longer works, or you cannot tolerate it, or there is no standard treatment available.
- You must be in generally good health with adequate organ function, like liver, kidney, and bone marrow.
- You must agree to use effective contraception during the study and for 6 months after.
- You must provide a tumor tissue sample (new or stored) if possible.
- You must not have certain other cancers, autoimmune diseases, or uncontrolled health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BM230) combined with a PD-1 inhibitor (a type of immunotherapy) for advanced cancers that have HER2. It aims to see if the combination is safe and effective in treating tumors that have stopped responding to standard treatments.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.